Medical Devices Fund

Need Help with the

Medical Devices Fund Application?

We Are Grant Experts

Call 1300 658 508

What is Medical Devices Fund?

The Medical Devices Fund is a competitive technology development and commercialisation program. It aims to provide support to individuals, companies, public and private hospitals, medical research institutes, universities and the medical devices industry, to take local innovation to market.



The Medical Devices Fund seeks to increase the uptake of NSW medical devices by the health system where they are cost effective and contribute to improved patient outcomes.

Since the first round in 2013, recipients of the NSW Medical Devices Fund have been awarded more than $70 million for 40 technologies. The fund invests in the development and commercialisation of medical devices and related technologies in NSW, with some past recipients later gaining high-profile investors.



The key objective of the Medical Devices Fund is to promote new and innovative medical devices/technologies within NSW that may have a global benefit.

Broadly, the Medical Devices Fund aims to:

  • provide support to individuals, companies, public and private hospitals, medical research institutes, universities, other public sector research organisations, and the medical devices industry, to take local innovation to market; and
  • increase the uptake of NSW medical devices by the health system where they are cost effective and contribute to improved patient outcomes.


We can help you prepare the Medical Devices Fund Application

Medical Devices Fund


Free. Instant. Download



The Medical Devices Fund has a total funding pool of approximately $8.2 million per annuum. The minimum grant available is $500,000 and the maximum is $5 million.


Eligible Projects

The following principles apply to the Medical Devices Fund:

  • The project must be capable of potentially:
    • improving patient care and/or health wellbeing
    • generating, economic, social and/or environmental benefits to NSW.
  • Funding will be open, competitive and merit-based, while maintaining commercial-in-confidence requirements.
  • Funding can be used for purposes including
    • proof-of-concept, prototyping and piloting studies
    • manufacturing samples for product trials
    • conducting market and product assessments
    • engaging a consultant to locate other national and international trials and research relevant to the product under development
    • and conducting clinical assessments
  • The fund will support a cross-section of products across a range of applications throughout the medical device product life-cycle (technical device concept demonstrated to marketing).
  • The fund will not support activities which are deemed to be research.
  • The Medical Devices Fund Expert Panel will have sufficient flexibility to tailor funding support according to what it believes is required to assist the development and commercialisation of a medical device.

To be considered for the Medical Devices Fund, the project:

  • must satisfy the definition of a medical device
  • must seek to progress a medical device along the commercialisation pathway
  • must be innovative (i.e. new to market, or new to world)
  • should have the potential to assist health delivery in NSW
  • must have been developed in NSW and derive health, economic, social and/or environmental benefit to NSW.


Eligible Applicants

The Medical Devices Fund can be accessed by eligible NSW organisations with innovative medical devices/technologies supported by intellectual
property. Eligible organisations include public and private hospitals, medical research institutes, universities, start-ups and established SMEs.

An applicant must be:

  • A financially viable company or commercial enterprise with the parent company based in NSW (e.g. location of manufacturing jobs, headquarters based in NSW, NSW investment,) and be able to provide evidence that the proposal connects and benefits NSW; have an Australian Business Number (ABN); typically with an annual turnover of less than $25 million; and is a legal entity; or
  • An individual based in NSW who agrees to form such an entity so that NSW Government can enter into legally binding funding agreements; or
  • A NSW public research organisation applying through its appropriate technology transfer office, or the CEO or equivalent of the research



Applications close 1 March 2022.


Government Grant Consultants

We Do Grants Everyday!

Call 1300 658 508

Medical Devices Fund

Free. Instant. Download


More Information

The Medical Devices Fund information provided is as guide only, please consult the source for the latest official information


2019 Medical Devices Fund Recipients

The 2019 NSW Medical Devices Fund Winners were:

  • Baymatob Pty Ltd ($2.96 million): Oli™, a non-invasive device for remote monitoring of pregnancy and labour progression
  • CleanSpace Technology Pty Ltd ($2.311 million): CleanSpace Halo is a re-useable respirator specifically designed in healthcare for pandemic preparedness
  • Beyond 700 Pty Ltd ($830,000): a camera that enables the invisible team film to be seen and observed
  • Perx Health ($748,000): a digital therapeutic that engages and motivates patients to better manage their conditions and form healthy habits.


2018 Medical Devices Fund Recipients

The 2018 NSW Medical Devices Fund Winners were:

  • Kico Knee Innovation Company Pty Ltd ($2.5 million): Customised total knee replacement technology platform. The platform has software and hardware components that provide orthopaedic surgeons and patients with dynamic, functional and patient-specific solutions. It is primarily aimed at Australian and US markets.
  • Ellen Medical Devices Pty Ltd ($2.2 million): An affordable dialysis system which will provide access to life-saving treatment to millions of kidney patients around the world. Dialysis is a safe and effective treatment for kidney failure, but expensive at $50,000-$100,000 per patient per annum in Australia.
  • Cenof ex Innovations Pty Ltd ($1.5 million): A device to improve treatment of side effects of the incurable chronic and painful disease, Lymphoedema. It is capable of activity moving lymphatic fluid while incorporating a patient’s need for comfort, portability, and ease. The disease can also lead to dangerous infections, restricted movement and depression.
  • iFix Medical Pty Ltd ($1.15 million): The iFix system can deliver a 3D-printed structure directly onto the eye to seal wounds in the treatment of corneal ulceration, better preventing infection, relieving pain and accelerating healing. The condition is extremely painful and accounts for 55,000 hospital presentation each year in Australia.
  • Eudaemon Technologies Pty Ltd ($1 million): A next-generation, non-allergenic condom made from hydrogels that act like latex rubber but with enhanced feel and self-lubrication and without odours or tastes. Although condoms can prevent both pregnancy and STIs they are often avoided due to the stigma of reduced sensation.
  • Trimph Technology Pty Ltd ($1 million): TrimphDent, a ready-to-use, injectable scaffold that is applied immediately after tooth extraction and has been shown to preserve the socket. Tooth extraction is an inherently traumatic procedure that damages the underlying tissues and leads to inevitable jaw bone shrinkage.
  • Indee Pty Ltd ($500,000): This inexpensive mechanical process to make gene-modified cells will solve the development and manufacturing issues associated with current gene therapies and ensure greater access to treatment. The impact of gene-modified cell therapies will be similar to that of antibiotics seen during the last century. In the near term, their therapies will provide cures for most cancers.


2017 Medical Devices Fund Recipients

The 2017 NSW Medical Devices Fund Winners were:

  • SpeeDx ($2.5 million), for the commercialisation of the first single test worldwide that detects sexually transmitted infections and antibiotic resistance.
  • MedLogical Innovations ($1.25 million), whose ProFocal-Rx drug allows more than 30% of prostate cancer patients to have minimally invasive therapy and preserve their prostate gland.
  • Baymatob ($1.47 million), whose non-invasive patch Oli is a capable of monitoring pregnancy and labour remotely, allowing for real-time observation.
  • Western Sydney Local Health District ($1.39 million), whose Mu Catheter reduces hypertension by de-nerving the renal artery using a transcatheter microwave.


2016 Medical Devices Fund Recipients

The 2016 NSW Medical Devices Fund Winners were:

  • Elastagen Pty Ltd ($4million) for Elastatherapy, a skin regeneration and wound repair product based on its unique tropoelastin-based biomaterial platform used in the surgical treatment of severe scars.
  • Nano-X Pty Ltd ($2.58million) for Nano‐X, a smarter and smaller cancer radiotherapy machine that will enable affordable, accessible best‐practice radiotherapy in resource‐limited areas.
  • Respiratory Innovations Pty Ltd ($1.3million) for Breathe Well, a device that provides breast cancer patients with breath hold instructions to reduce the risk of radiotherapy causing unnecessary and potentially fatal radiation heart damage.
  • HEARworks Pty Ltd ($750,000) for the development of the Auditory Cortical Discrimination (ACORD) test to assist clinicians in deciding which hearing‐impaired infants should receive cochlear implants.


2015 Medical Devices Fund Recipients

The 2015 NSW Medical Devices Fund Winners were:

  • PAFtec Australia ($2,196,000): for CleanSpaceTM Respirators, the smallest and lightest powered respirators in the world and a game changer for respiratory protection.
  • Atomo Diagnostics ($1,800,000): for an innovative ‘all-in-one’ rapid point of care HIV diagnostic test device that replaces the need for multiple kit components and extensive procedural steps. PAFtec is an ATP Innovations portfolio company.
  • AllVascular ($1,750,000): for a novel Arterial & Venous Access System (AVAS) that allows clinicians to isolate the liver when delivering anti-cancer agents, minimising whole body side effects and reducing treatment time.
  • University of New South Wales ($1,590,000): for Thru-FuzeTM Spinal fusion, a new orthopaedic device for fusion of adjacent spinal vertebrae to help alleviate chronic back pain, such as that caused by degenerative disc disease.
  • Kleer-i ($1,314,000): for a breakthrough next-generation biological “patch”, which is bonded over an eye wound by a low-powered laser to seal lacerations and deliver faster wound repair, without loss of vision from scarring or infection. Kleer-i is a graduate of the NSW Medical Device Commercialisation Training Program 2015.
  • cmee4 Productions ($1,078,740): for Sound Scouts, a novel mobile game to check a child’s hearing before or during their first year of school. It aims to detect undiagnosed hearing issues that could affect their social or academic development.
  • Maverick Biomaterials ($337,500): for innovative materials used in the manufacture of cardiovascular devices implanted via keyhole surgery, reducing the patient’s time in intensive care facilities.
  • One special grant of $199,000 was awarded to Nano-X for a new radiotherapy machine that will transform global access to cancer care. Nano-X is a graduate of the NSW Medical Device Commercialisation Training Program 2014 and an ATP Innovations portfolio company.


Latest News

EMVision receives $2.5 million from the NSW Health Medical Devices Fund to support its multi-site clinical trial to validate the effectiveness of their portable, high-speed neuro-imaging technology for stroke diagnosis.

EMVision (ASX:EMV) is an innovative medical device company developing portable electromagnetic microwave imaging solutions.



EMVision Medical Devices (EMV) has been awarded a $2.5 million grant to support clinical studies, and repay the grant upon reaching a positive EBITDA.

EMVision (ASX:EMV) is an innovative medical device company developing portable electromagnetic microwave imaging solutions. 


What is the #1 grant for start-ups?

12,000+ companies access the R&D tax incentive per year that yields a CASH REBATE of up to 43.5%.
This might be perfect your start up.
Do you want to know more?

Scroll to Top
R&D Top 10 Consultant Tips

Top 10 Consultant Tips to Maximise the R&D Tax Incentive